Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 27, 2017, reports the completion of a private placement equity offering by Citius Pharmaceuticals, Inc. The filing details the final closing of the offering and the terms of the associated transaction documents.
Key Financial Metrics
- Gross Proceeds: $768,100
- Units Sold: 1,920,250 Units (each consisting of one share of common stock and one warrant)
- Price per Unit: $0.40
- Placement Agent Fees: $174,853 total ($75,000 in administrative/legal fees, $99,853 in expense allowance and cash commission)
- Placement Agent Warrants: 192,025 warrants issued to the agent
Material Changes
The primary material change is the increase in outstanding equity securities following the sale of 1,920,250 shares of common stock and the issuance of corresponding warrants. The filing does not provide comparative financial data (revenue, profit, or cash flow) as this is a transaction-specific report rather than a periodic financial statement.
Transaction Terms and Outlook
- Warrant Terms: Investor warrants have an exercise price of $0.55 and are exercisable for five years from issuance.
- Placement Agent Compensation: The agent received a 10% cash commission, a 3% expense allowance, and warrants equal to 10% of the units sold.
- Regulatory Status: Securities were sold pursuant to exemptions under Section 4(a)(2) and Rule 506 of Regulation D of the Securities Act of 1933.
- Future Filings: Full terms of the Transaction Documents will be included in the Form 10-Q for the quarter ended March 31, 2017.
Investor Verification Checklist
- Verify the exact number of shares issued and the dilution impact on existing shareholders.
- Confirm the net proceeds to the company after deducting the $174,853 in placement agent fees.
- Review the upcoming Form 10-Q for the complete text of the Unit Purchase Agreement and Placement Agency Agreement.
- Check the current trading price of the stock relative to the $0.55 warrant exercise price.